----item----
version: 1
id: {CB6E5C21-2361-4A6B-B650-5819BEFAB4F3}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/09/24/Video Chris Viehbacher Interviewed At BioPharm America
parent: {D0AAADAC-3A4D-4719-8453-0B9B929C7097}
name: Video Chris Viehbacher Interviewed At BioPharm America
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 64cb1a10-4c67-457b-b254-b29a6d9ca527

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 58

 Video: Chris Viehbacher Interviewed At BioPharm America  
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 54

Video Chris Viehbacher Interviewed At BioPharm America
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1200

<p> Since his departure from Sanofi, Christopher Viehbacher has taken on a significant role in venture capital. At the BioPharm America 2015 conference in Boston, Massachusetts, he spoke about his company's business model and goals, as well as the trend of pharma execs moving into smaller companies. </p> <p> After departing unceremoniously from his position as CEO of Sanofi last year, Viehbacher has moved into the venture capital realm, now serving as managing partner of Boston-based Gurnet Point Capital. Prior to addressing the conference on Sept. 15, Viehbacher spoke with <i>Scrip</i>'s sister publication &quot;The Pink Sheet&quot; about the recent trend of big pharma executives moving into roles with smaller companies putting them closer to innovation as well as about the deal-making atmosphere in biopharmaceuticals. </p> <p> <b>BioPharm America 2015: Interview with Christopher Viehbacher </b> </p> <p> <preform><iframe src="https://www.youtube.com/embed/LLtyJzovKTI?rel=0" frameborder="0" allowfullscreen=""></iframe></preform></p> <p> Now managing partner at Gurnet Point Capital, Viehbacher spoke about deal-making and other industry trends. </p> <p> <i>SOURCE: EBD Group</i> </p> 
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 305

<p> Since his departure from Sanofi, Christopher Viehbacher has taken on a significant role in venture capital. At the BioPharm America 2015 conference in Boston, Massachusetts, he spoke about his company's business model and goals, as well as the trend of pharma execs moving into smaller companies. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 54

Video Chris Viehbacher Interviewed At BioPharm America
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150924T184510
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150924T184510
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150924T184510
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029867
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 58

 Video: Chris Viehbacher Interviewed At BioPharm America  
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{EABD3322-E3F8-4F5F-905F-C400968461EA}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

360581
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042455Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

64cb1a10-4c67-457b-b254-b29a6d9ca527
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042455Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
